Patent registration for Redosemtide\u2019s use in cartilage diseases in Korea is anticipated. No impact on the FY2027 July period; further disclosures will be notified as they arise.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"StemRIM","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4599-20260925-03.pdf","jir_short_summary":"Patent registration for Redosemtide\u2019s use in cartilage diseases in Korea is anticipated. No impact on the FY2027 July period; further disclosures will be notified as they arise.","jir_summary":"### Overview\nThis news brief communicates the expectation that Korea-wide patent registration for Redosemtide is likely to be determined. The patent covers uses as a therapeutic for cartilage diseases (traumatic cartilage defects, osteoarthritis, osteochondritis dissecans), with StemRIM Co., Ltd. and Osaka University as applicants. The expansion of Redosemtide\u2019s indications is under consideration, and completion of registration is expected to secure development potential in the Korean market.\n\n### Impact on shareholders and outlook\nThe patent registration does not specify any direct financial impact, and there is no effect on the full-year results for the fiscal year ending July 2027. Future disclosures may be issued as the patent registration progresses or new indications are developed.","jir_financial_highlights":"Impact on full-year results for the fiscal year ending July 2027: Unknown (Unknown)","jir_category":"","jir_hashtags":"#StemRIM, #RegenerativeMedicine, #PatentRegistration, #Cartilage, #DisclosureUpdate","jir_key_figures":"Patent filing region: Korea\nFiling number: 10-2021-7015301\nRegistration (publication) number: TBD","jir_meta_title":"StemRIM: Notice of patent registration for cartilage-disease use in Korea | September 25, 2026","jir_meta_description":"Notice of patent registration for Redosemtide's use in cartilage diseases in Korea. No expected impact on 2027 fiscal year results. Monitor for future disclosures.","jir_og_title":"StemRIM: Korea cartilage-disease patent registration notice","jir_og_description":"Notice regarding patent registration for Redosemtide in Korea. No impact on the 2027 fiscal year; watch for progress.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58113,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-123179","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n